Carlsmed (CARL)
Builds personalized spine-fusion implant kits from AI-enabled surgical plans.
$14.85
vs last close−0.57 (−3.70%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 5 | 6 | 7 | 9 | 10 | 12 | 13 | 15 | 16 | 19 |
| Cost of revenue | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 4 |
| Gross profit | 3 | 4 | 5 | 5 | 7 | 8 | 9 | 10 | 12 | 12 | 15 |
| 9 | 9 | 11 | −3 | 51 | 13 | 15 | 19 | 21 | 22 | 26 | |
| Research & development | 0 | 3 | 4 | 4 | 3 | 3 | 4 | 4 | 5 | 5 | 6 |
| 9 | 6 | 7 | 9 | 9 | 10 | 11 | 15 | 16 | 17 | 20 | |
| Selling & marketing | 0 | 4 | 5 | 7 | 6 | 7 | 8 | 10 | 11 | 10 | 12 |
| General & administrative | 0 | 2 | 2 | 2 | 2 | 3 | 3 | 5 | 5 | 6 | 8 |
| Other expenses | 0 | 0 | 0 | −16 | 39 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −5 | −5 | −6 | 8 | −44 | −6 | −7 | −9 | −9 | −9 | −11 |
| 0 | 0 | 0 | −16 | 39 | 0 | 0 | 1 | 1 | 1 | 11 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 15 | −39 | 0 | 0 | −1 | −1 | −1 | −11 |
| Income before tax | −6 | −5 | −6 | −8 | −5 | −6 | −7 | −9 | −9 | −9 | 0 |
| Net income from continuing operations | −6 | −5 | −6 | −8 | −5 | −6 | −7 | −9 | −9 | −9 | 0 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −11 |
| Net income | −6 | −5 | −6 | −8 | −5 | −6 | −7 | −9 | −9 | −9 | −11 |
| EPS, basic | −$0.21 | −$1.36 | −$1.55 | −$1.83 | −$0.18 | −$0.33 | −$1.47 | −$0.40 | −$0.25 | −$0.32 | −$0.39 |
| EPS, diluted | −$0.21 | −$1.36 | −$1.55 | −$1.83 | −$0.18 | −$0.33 | −$1.47 | −$0.40 | −$0.25 | −$0.32 | −$0.39 |
| Weighted average shares, basic | 27 | 4 | 4 | 5 | 27 | 19 | 5 | 21 | 14 | 27 | 27 |
| Weighted average shares, diluted | 27 | 4 | 4 | 5 | 27 | 19 | 5 | 21 | 14 | 27 | 27 |
| EBITDA | −6 | −5 | −6 | −7 | −4 | −5 | −6 | −8 | −8 | −8 | 0 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −6 | −5 | −6 | −7 | −4 | −5 | −6 | −8 | −8 | −8 | 0 |
